Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma.

ABSTRACT: Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The research on predictive biomarkers in metastatic CRC (mCRC) mainly focused on the identification of biomarkers of response or resistance to anti-epidermal growth factor receptor monoclonal antibodies. In this respect, international guidelines suggest testing mCRC patients only for KRAS, NRAS and BRAF mutations and for microsatellite instability. However, the use of novel testing methods is raising relevant issue related to these biomarkers, such as the presence of sub-clonal RAS mutations or the clinical interpretation of rare no-V600 BRAF variants. In addition, a

SUBMITTER: Rachiglio AM 

PROVIDER: S-EPMC9400741 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature